WO2005028616A3 - Morphogen compositions and methods of use thereof to treat heart disorders - Google Patents

Morphogen compositions and methods of use thereof to treat heart disorders Download PDF

Info

Publication number
WO2005028616A3
WO2005028616A3 PCT/US2004/022328 US2004022328W WO2005028616A3 WO 2005028616 A3 WO2005028616 A3 WO 2005028616A3 US 2004022328 W US2004022328 W US 2004022328W WO 2005028616 A3 WO2005028616 A3 WO 2005028616A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
morphogen
compositions
human
treat heart
Prior art date
Application number
PCT/US2004/022328
Other languages
French (fr)
Other versions
WO2005028616A2 (en
WO2005028616A9 (en
Inventor
Douglas W Losordo
Original Assignee
Caritas St Elizabeths Boston
Douglas W Losordo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caritas St Elizabeths Boston, Douglas W Losordo filed Critical Caritas St Elizabeths Boston
Publication of WO2005028616A2 publication Critical patent/WO2005028616A2/en
Publication of WO2005028616A9 publication Critical patent/WO2005028616A9/en
Publication of WO2005028616A3 publication Critical patent/WO2005028616A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are compositions and methods for preventing, treating, or reducing symptoms associated with a myocardial or related disorder such as an infarction. In one embodiment, the method includes administering a therapeutically effective amount of a nucleic acid encoding at least one morphogen; or an effective fragment thereof. Preferred morphogens include the human Sonic Hedghog (Shh), human Desert Hedgehog (Dhh), and human Indian Hedgehog (Ihh) proteins. The methods can be used alone or in combination with other methods involving administration of an angiogenic protein, hematopoietic protein, or endothelial precursor cells (EPCs).
PCT/US2004/022328 2003-07-24 2004-07-09 Morphogen compositions and methods of use thereof to treat heart disorders WO2005028616A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49006403P 2003-07-24 2003-07-24
US60/490,064 2003-07-24

Publications (3)

Publication Number Publication Date
WO2005028616A2 WO2005028616A2 (en) 2005-03-31
WO2005028616A9 WO2005028616A9 (en) 2005-06-09
WO2005028616A3 true WO2005028616A3 (en) 2006-06-01

Family

ID=34375225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/022328 WO2005028616A2 (en) 2003-07-24 2004-07-09 Morphogen compositions and methods of use thereof to treat heart disorders

Country Status (1)

Country Link
WO (1) WO2005028616A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1556057A4 (en) 2002-08-29 2009-07-15 Univ California Agents and methods for enhancing bone formation
WO2005020928A2 (en) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
EP1993558B1 (en) 2006-02-27 2014-07-30 The Regents of The University of California Oxysterol compounds and the hedgehog pathway
US8022052B2 (en) 2006-12-19 2011-09-20 The Regents Of The University Of California Inhibition of PPAR gamma expression by specific osteogenic oxysterols
EP2146724A2 (en) * 2007-03-16 2010-01-27 The Regent of the University of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
EP2231164A1 (en) 2007-12-03 2010-09-29 The Regents of the University of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
JP6262723B2 (en) 2012-05-07 2018-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ Oxysterol analog OXY133 induces bone development and hedgehog signaling and inhibits adipogenesis
ES2667814T3 (en) 2013-01-14 2018-05-14 Institut National De La Santé Et De La Recherche Médicale (Inserm) Pharmaceutical compositions for cardioprotection
US9683009B2 (en) 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027995A1 (en) * 1996-12-20 1998-07-02 Creative Biomolecules, Inc. Treatment of mammalian myocardium with morphogen locally, or with morphogenically-treated myogenic precursor cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027995A1 (en) * 1996-12-20 1998-07-02 Creative Biomolecules, Inc. Treatment of mammalian myocardium with morphogen locally, or with morphogenically-treated myogenic precursor cells

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALEXANDER M.Y. ET AL.: "Gene Transfer and Models of Gene Therapy for the Myocardium", CLIN. EXP. PHARMACOL. PHYSIOL., vol. 26, 1999, pages 661 - 668, XP002925647, DOI: doi:10.1046/j.1440-1681.1999.03117.x *
FREEDMAN M.B. ET AL.: "Therapeutic Angiogenesis of Coronary artery Disease", ANNALS OF INTERNAL MEDICINE, vol. 136, no. 1, January 2002 (2002-01-01), pages 54 - 71, XP002531912 *
HEDMAN M. ET AL.: "Safety and Feasibility of Catheter-based Local intracoronary VEGF gene transfer in Prevention of Postangioplasty", CIRCULATION, vol. 107, 2003, pages 2677 - 2683 *
HEILMANN C.A. ET AL.: "Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myodardial ischemia", EUR. J. CARDIOTHORAC. SURG., vol. 24, no. 5, November 2003 (2003-11-01), pages 785 - 793, XP027130381 *
MORISHITA R.: "Recent Progress in Gene Therapy for Cardiovascular Disease", CIRC. J., vol. 66, December 2002 (2002-12-01), pages 1077 - 1086 *
POLA R. ET AL.: "The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors", NAT. MED., vol. 7, no. 6, June 2001 (2001-06-01), pages 706 - 711, XP002207334, DOI: doi:10.1038/89083 *
VILLAVICENCIO H. ET AL.: "The Sonic Hedgehog-Patched-Gli Pathway in Human development and Disease", AM. J. HUM. GENET., vol. 67, 2000, pages 1047 - 1054 *
YLA-HERTTUALA S. AND ALITALO K.: "Gene transfer as a tool to induce therapeutic vascular growth", NAT. MED., vol. 9, no. 6, June 2003 (2003-06-01), pages 694 - 701, XP002561932, DOI: doi:10.1038/nm0603-694 *

Also Published As

Publication number Publication date
WO2005028616A2 (en) 2005-03-31
WO2005028616A9 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
ECSP056076A (en) SUPPLY SYSTEM FOR DRUG AND CELL THERAPY
BR0014512A (en) Topical treatment for streptococcal infections
AU6323001A (en) Treatment of acute coronary syndrome with glp-1
NO20051934L (en) Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders.
WO2002009690A3 (en) Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent
WO2007125545A3 (en) Transmucosal composition
BR9811825A (en) Use of lactobacillus to reduce the level of fibrinogen in the blood
EP2330111A3 (en) Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
NO20023473D0 (en) Compositions for the Delivery of a Cortisol Antagonist
WO2007035474A3 (en) Transdermal delivery peptides and method of use thereof
WO2002004421A3 (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
WO2004087212A3 (en) Nitric oxide in treatment of inflammation
BR9809951A (en) Method for treating obesity
IL167890A (en) Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome
WO2005028616A3 (en) Morphogen compositions and methods of use thereof to treat heart disorders
WO2008070264A3 (en) Nasal spray composition and method for treating rhinitis, sinusitis or both
EP1153607A3 (en) Growth hormone for the treatment of joint inflammation
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
Feng et al. Preventive effect of a proteasome inhibitor on the formation of accelerated atherosclerosis in rabbits with uremia
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2001026639A3 (en) Pharmaceutical composition of ateglinide and another antidiabeticagent
HK1052139A1 (en) Method and composition for the treatment of adenoviral ocular infections
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
SE0000303D0 (en) Novel compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/20-20/20, DRAWINGS, REPLACED BY NEW PAGES 1/27-27/27; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase